The Sentio device is intended for patients with conductive or mixed hearing loss, particularly those with outer ear deformities. It is effective alternative for individuals unable to use traditional hearing aids. This study aimed to evaluate the implant's effectiveness in eight patients diagnosed with conductive or mixed hearing loss.
All patients received a unilateral Sentio implant. Pure-tone audiometry was performed before surgery and one month after implant activation. Speech understanding in quiet was assessed using verbal audiometry with the Demenko and Pruszewicz monosyllabic word test. Speech understanding in noise was evaluated using the Polish Matrix Sentence Test. Patients completed the Abbreviated Profile of Hearing Aid Benefit questionnaire to assess subjective impressions before and after surgery.
One month after implant activation, patients demonstrated statistically significant improvements in hearing and speech comprehension. Speech discrimination under free-field conditions improved, increasing from 5.5% to 94.5%. Results from the Matrix test showed an improvement in speech perception in noise. The APHAB questionnaire results revealed a notable decrease in perceived hearing difficulties.
One month after activation, the Sentio implant significantly improved hearing thresholds across key frequencies and enhanced speech understanding in quiet and noise. Subjective assessments indicated a notable reduction in hearing difficulties, particularly in ease of communication, background noise, and reverberation. The smaller size of the Sentio implant allows for its use in challenging anatomical conditions. Sentio represents an effective alternative for individuals with conductive or mixed hearing loss who cannot benefit from conventional hearing aids.

Background: The aim of this study was to compare measures of implant survival, time to loading and post-operative outcomes between 3- and 4mm implant lengths for percutaneous bone anchored hearing system (BAHS). Most implants inserted are 4mm in length, with 3mm length implants primarily used for children or for adults with thinner bone, which is comparatively less common. This investigation expands the understanding of the outcomes related to percutaneous BAHS for adults in general and for the 3mm implants in particular.

Methods: A single-center, retrospective review of medical records was conducted for 234 subjects, including a total of 240 wide implants, equally distributed among implant lengths. (Clinicaltrials.gov identifier: NCT06421766)

Results: Out of 240 implants, 238 (99%) were found to be in situ at 3 months after surgery, with no significant difference observed between the 3- and 4mm implant groups. Long-term survival remained high with 232 (97%) of implants still in situ after an average observation period of 43±40 months. Time to loading was influenced by clinical practice developments rather than implant length, with longer time to loading (70±39 days) for earlier implantations compared to more recent implantations (50±15 days). There was no significant difference in the frequency of reported complications (e.g. inflammation, infection, pain) during the initial postoperative period between subjects who had received 3mm or 4mm implants.

Conclusion: Similar implant survival, reliability and post-operative outcomes can be expected from both 3- and 4mm implant lengths in the general adult population.

Background:
The Bonebridge and Vibrant Soundbridge are well established implantable hearing devices. The aim of this study was to look at both short and long term outcomes for Bonebridge and Soundbridge devices at a single centre with two surgeons. 
Methods:
Retrospective review of audiological outcome data including pre-operative and post-operative pure tone audiograms, as well as pre-operative and post-operative speech outcomes. Long term audiological outcome data was reviewed. Surgical techniques and correlation with patient outcomes were also considered.
Results:
A total of 37 patients had a Bonebridge implant, with 3 bilateral sequential fits. A total of 47 patients had a Vibrant Soundbridge, with 16 bilateral sequential fits. The longest follow up was 13 years. Consistent improvement in audiological outcome data pre to post implant were noted in all cases. Factors which may contribute to reduced likelihood of success were noted in frail and comorbid patients. There were patterns noted in patients requiring explantation in relation to the surgical technique utilised.
Conclusions: The results demonstrate reliable improvement in hearing and functional gain with both the Bonebridge and Vibrant Soundbridge devices. There are factors which can help with pre-operative patient selection as well as surgical approach to minimise risk of complications.